New Technical Note: Independent evaluation of the VirClia® Dengue IgM assay
A new independent evaluation carried out at the University Hospital of Lille, with the support of the French Reference Center for Arboviruses, has recently been published in the Journal of Tropical Medicine.
This work represents the first independent assessment of the fully automated VirClia® Dengue IgM assay in a non-endemic European setting. The study compared VirClia® results with RT-PCR and conventional ELISAs (in-house and Euroimmun), across a total of 104 clinical samples collected in France.
Key findings
The results confirm that VirClia® Dengue IgM provides excellent performance from day five after symptom onset:
- Sensitivity: 95.7%
- Specificity: 96.4%
The strong agreement with both RT-PCR and Euroimmun ELISA further demonstrates the reliability of VirClia® in clinical practice.
Practical advantages for laboratories
Beyond analytical performance, the authors emphasize the benefits of the VirClia® monotest format:
- Fully automated workflow
- Rapid turnaround times
- Flexibility to process individual samples without batch requirements
These features are particularly valuable for laboratories in non-endemic regions, such as France, where incidence remains low but is on the rise.
🔗 Click here to access the full technical note.